By Novo Nordisk…
To get in touch with Novo Nordisk Pharmatech showing insulin boost to cell line growth at BPI 2017 Boston, simply fill out the form below.
Subscribe to Supplier
Novo Nordisk Pharmatech showing insulin boost to cell line growth at BPI 2017 Boston
Koege, Denmark: – Novo Nordisk Pharmatech A/S, the leading worldwide supplier of high-quality ingredients for the biopharmaceutical, pharmaceutical and personal care industries, will attend this year’s BioProcess International (BPI) conference in the USA as a participant and exhibitor.
The Novo Nordisk Pharmatech stand at Booth 1031 at the Hynes Center in Boston will highlight advances that the organization has achieved in promoting recombinant cells using latest Insulin technology to improve cell growth and influenza vaccine yield in HEK293 suspension cell line.
Boosted cell growth and density
“We believe professionals working in R&D or product development in cell culture will be highly interested in the advances we have been able to achieve in cell growth, productivity and cell density,” commented Novo Nordisk Pharmatech Product Manager, Magnus Franzmann.
The use of insulin, a protein currently used and approved in several processes and production platforms, as an additive to boost cell growth and viral production is seen as a promising avenue for production of large quantities of vaccines in a more rapid and cost-effective way, overcoming implementation challenges associated with major changes to current bioprocesses due to costs associated with the regulatory approval process.
Canadian NRC study
The use of HEK293SF-3F6 as a GMP cell line adapted to growth in suspension in serum-free conditions was presented in a recent webinar featuring Dr. Aziza Manceur, Research Officer with Canada’s National Research Council (NRC).
With addition of 10mg/L insulin, the NRC team was able to achieve a four-fold increase in cell growth, reaching maximal cell density within six days instead of the previous 10 days.
The webinar is still available to view on the BPI website.
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.
The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.
All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.
For Financial Year 2015, Novo Nordisk reported world sales totaling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.
About BioProcess International 2017
The BioProcess International (BPI) Conference & Exhibition is the world’s largest event dedicated to bioprocessing, dedicated to highlighting the sciences, technologies and partners needed to accelerate promising biologics to market.
BPI 2017 is a four-day event opening September 25 at the Hynes Convention Center in Boston, Massachusetts.
The conference is expected to attract more than 1800 scientists and executives representing some 300 companies and organizations working across the entire bioprocessing spectrum. The co-located exhibition will feature more than 160 leading companies.
The event is organized by Knect365 with more information at: https://lifesciences.knect365.com/bioprocessinternational/